Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus

Table 1 Baseline characteristics of overall patients n (%)

Characteristic	Group A	Group B
	(n = 37)	(n = 31)
Sex
Male	34 (91.9)	26 (83.9)
Female	3 (8.1)	5 (16.1)
Age, yr (%)
≥ 55 yr	18 (48.9)	14 (45.2)
< 55 yr	19 (51.4)	17 (54.8)
Type of tumor
Nodular	30 (81.1)	29 (93.5)
Infiltrative	7 (18.9)	2 (6.5)
HCC maximum diameter
≥ 5 cm	26 (70.3)	19 (61.3)
< 5 cm	11 (29.7)	12 (38.7)
Degree of MPVTT
Stenosis	31 (83.8)	24 (77.4)
Occlusive	6 (16.2)	7 (22.6)
Child-pugh class
A	33 (89.2)	24 (77.4)
B	4 (10.8)	7 (22.6)
ECOG performance status
0/1	33 (89.2)	26 (83.9)
2	4 (10.8)	5 (16.1)
Etiology of liver disease
HBV	35 (94.6)	29 (93.5)
Other	2 (5.4)	2 (6.5)
Serum AFP level (in ng/mL)
≥ 400	20 (54.1)	17 (54.8)
< 400	17 (45.9)	14 (45.2)
Extrahepatic metastasis	3 (8.1)	3 (9.7)

AFP: Alfa-fetoprotein; ECOG: Eastern cooperative oncology group; HBV: Hepatitis B virus; MPVTT: Main portal vein tumor thrombus; HCC: Hepatocellular carcinoma.